KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Work In Process (2021 - 2025)

Bionano Genomics (BNGO) has disclosed Work In Process for 5 consecutive years, with $388000.0 as the latest value for Q3 2025.

  • Quarterly Work In Process fell 89.17% to $388000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $388000.0 through Sep 2025, down 89.17% year-over-year, with the annual reading at $2.3 million for FY2024, 76.01% down from the prior year.
  • Work In Process hit $388000.0 in Q3 2025 for Bionano Genomics, down from $653000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $10.6 million in Q2 2023 to a low of $388000.0 in Q3 2025.
  • Historically, Work In Process has averaged $5.6 million across 5 years, with a median of $5.8 million in 2022.
  • Biggest five-year swings in Work In Process: skyrocketed 325.0% in 2022 and later tumbled 89.17% in 2025.
  • Year by year, Work In Process stood at $1.7 million in 2021, then surged by 325.0% to $7.1 million in 2022, then soared by 38.77% to $9.8 million in 2023, then tumbled by 76.01% to $2.3 million in 2024, then crashed by 83.48% to $388000.0 in 2025.
  • Business Quant data shows Work In Process for BNGO at $388000.0 in Q3 2025, $653000.0 in Q2 2025, and $1.6 million in Q1 2025.